With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.

The moderate to severe atopic dermatitis market is experiencing strong growth driven by rising global prevalence and heightened awareness, fueling demand for advanced treatments. Breakthroughs in ...

New biologic and targeted therapies are changing the landscape of prurigo nodularis care, offering sustained relief and ...

Coming up: Upcoming phase 3 data later in 2025 includes Repatha cardiovascular outcomes data for a broader group of patients, more studies for atopic dermatitis drug candidate rocatinlimab ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Amgen's diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, but ...

Another important candidate, rocatinlimab, is being evaluated in phase III studies for atopic dermatitis and prurigo nodularis. Several data readouts are expected over the next six to 12 months ...

We also announced positive data from Phase III studies of rocatinlimab, UPLIZNA and IMDELLTRA, while initiating multiple Phase III trials of MariTide and TEZSPIRE. Let's begin with MariTide ...